CHALLENGES IN DEVELOPING VACCINE FOR CANINE DISTEMPER

MT AHMAD; HA HASHMI; MU HASSAN; A KHALIQ; SKA SHAH; B MAQBOOL; A EJAZ; S JAMIL; MU REHMAN; A FRAZ

doi:10.54112/bcsrj.v2024i1.1159

Authors

MT AHMAD Department of Pathology, University of Veterinary and Animal Sciences Lahore, Punjab, Pakistan
HA HASHMI Department of Clinical Studies, Faculty of Veterinary and Animal Sciences, PMAS Arid Agriculture University, Rawalpindi, Punjab, Pakistan
MU HASSAN University of Veterinary and Animal Sciences, Lahore, Subcampus CVAS, Jhang, Punjab, Pakistan
A KHALIQ Department of Livestock and Dairy Development, Balochistan, Pakistan
SKA SHAH Department of Veterinary and Animal Sciences, The University of Veterinary and Animal Sciences, Swat, KPK, Pakistan
B MAQBOOL Department of Veterinary Medicine, Faculty of Veterinary and Animal Sciences, The University of Agriculture, Dera Ismail Khan, KPK, Pakistan
A EJAZ Department of Pharmacy, Islamia University Bahawalpur, Punjab, Pakistan
S JAMIL Faculty of Animal Husbandry and Veterinary Sciences, The University of Agriculture Peshawar, KPK, Pakistan
MU REHMAN Department of Animal Husbandry, The University of Agriculture Peshawar, KPK, Pakistan
A FRAZ Foot and Mouth Disease Research Centre, Lahore, Punjab, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.1159

Keywords:

Canine Distemper Virus, vaccine development, immune evasion, nanoparticle vaccines, cross-species transmission, immunization coverage, One Health approach

Abstract

The Canine Distemper Virus (CDV) represents a considerable risk to domestic and wild carnivore populations globally, notwithstanding the existence of vaccinations. This study examines the significant obstacles in creating successful CDV vaccines, especially regarding virus evolution, immune evasion, cross-species transmission, and vaccine reluctance. This review aims to consolidate existing research on CDV vaccine development, emphasizing emerging technologies, such as nanoparticle and DNA vaccines, and their capacity to address present challenges in immunogenicity and cross-species protection. Through the analysis of recent findings, this review delineates significant gaps in the comprehension of CDV's genetic variety of CDVs, the sustainability of wildlife reservoirs, and the obstacles to attaining extensive vaccination coverage. This review evaluates the influence of public health infrastructure and socioeconomic factors on vaccination distribution and uptake constraints, particularly in developing areas. These findings highlight the significance of a One Health approach, which amalgamates veterinary, wildlife, and public health viewpoints to address CDV epidemics more efficiently. Future research should focus on augmenting vaccine efficacy in non-domestic species, increasing public awareness of immunization initiatives, and creating thermostable vaccines for improved distribution accessibility. This review offers critical insights into the intricacies of the CDV vaccination and presents a framework for enhancing worldwide initiatives to combat this destructive virus.

Downloads

Download data is not yet available.

References

Karki M, Rajak KK, Singh RPJV. Canine morbillivirus (CDV): a review on current status, emergence and the diagnostics. 2022;33(3):309-21.

Mattiuzzi C, Lippi GJC. Long COVID: an epidemic within the pandemic. MDPI; 2023. p. 773-6.

Ji Y, Yaseen F, Sohail MJFiP. Life orientation and psychological distress in COVID recovered patients-the role of coping as a mediator. 2022;13:997844.

Sadarangani M, Marchant A, Kollmann TRJNRI. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. 2021;21(8):475-84.

Echeverry-Bonilla DF, Buriticá-Gaviria EF, Orjuela-Acosta D, Chinchilla-Cardenas DJ, Ruiz-Saenz JJV. The First Report and Phylogenetic Analysis of Canine Distemper Virus in Cerdocyon thous from Colombia. 2022;14(9):1947.

Nguyen B, Tolia NHJnV. Protein-based antigen presentation platforms for nanoparticle vaccines. 2021;6(1):70.

Polykretis P, Donzelli A, Lindsay JC, Wiseman D, Kyriakopoulos AM, Mörz M, et al. Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues. 2023;56(1):2259123.

Beyer DK, Forero AJJomb. Mechanisms of antiviral immune evasion of SARS-CoV-2. 2022;434(6):167265.

Moreira P, Sequeira AM, Pereira S, Rodrigues R, Rocha M, Lousa DJapa. ViralFP: A webserver of viral fusion proteins. 2021.

Kasuga Y, Zhu B, Jang K-J, Yoo J-SJE, medicine m. Innate immune sensing of coronavirus and viral evasion strategies. 2021;53(5):723-36.

Porto PS, Anjos D, Dabilla N, da Fonseca SG, Souza MJI, Genetics, Evolution. Immunoinformatic construction of an adenovirus-based modular vaccine platform and its application in the design of a SARS-CoV-2 vaccine. 2020;85:104489.

Dantzler KW, de la Parte L, Jagannathan PJC, immunology t. Emerging role of γδ T cells in vaccine‐mediated protection from infectious diseases. 2019;8(8):e1072.

Rouzine IM, Rozhnova GJCm. Evolutionary implications of SARS-CoV-2 vaccination for the future design of vaccination strategies. 2023;3(1):86.

Li X, Liu S, Yin P, Chen KJFiI. Enhanced immune responses by virus-mimetic polymeric nanostructures against infectious diseases. 2022;12:804416.

Brisse M, Vrba SM, Kirk N, Liang Y, Ly HJFii. Emerging concepts and technologies in vaccine development. 2020;11:583077.

Guimaraes LC, Costa PAC, Scalzo Júnior SRA, Ferreira HAS, Braga ACS, de Oliveira LC, et al. Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models. 2024;15(1):590.

Lee K-W, Yam JWP, Mao XJC. Dendritic cell vaccines: A shift from conventional approach to new generations. 2023;12(17):2147.

Zhao J, Ren Y, Chen J, Zheng J, Sun DJV. Viral pathogenesis, recombinant vaccines, and oncolytic virotherapy: applications of the canine distemper virus reverse genetics system. 2020;12(3):339.

Rajabimajd N, Alimoradi Z, Griffiths MDJAJoSH, Behavior. Impact of COVID-19-related fear and anxiety on job attributes: a systematic review. 2021;4(2):51-5.

Thumbi S, Blumberg L, Le Roux K, Salahuddin N, Abela BJTL. A call to accelerate an end to human rabies deaths. 2022;400(10369):2261-4.

Files MA, Kristjansson KM, Rudra JS, Endsley JJJFiM. Nanomaterials-based vaccines to target intracellular bacterial pathogens. 2022;13:1040105.

Lu B, Lim JM, Yu B, Song S, Neeli P, Sobhani N, et al. The next-generation DNA vaccine platforms and delivery systems: Advances, challenges and prospects. 2024;15:1332939.

Rojas JM, Sevilla N, Martín V. Chapter Adenovirus as Tools in Animal Health. 2019.

Yang D-K, Park Y-R, Kim H-H, Kim E-J, Lee HJ, Hyun B-HJJoB, et al. Biological and Genetic Characterization of Canine Distemper Virus Vaccine Candidate Named as CD1901-100. 2022;52(2):72-81.

Rendon-Marin S, da Fontoura Budaszewski R, Canal CW, Ruiz-Saenz JJVj. Tropism and molecular pathogenesis of canine distemper virus. 2019;16:1-15.

Kotraiah V, Phares TW, Browne CD, Pannucci J, Mansour M, Noe AR, et al. Novel peptide-based PD1 immunomodulators demonstrate efficacy in infectious disease vaccines and therapeutics. 2020;11:264.

Chiang H-S, Liu HMJFii. The molecular basis of viral inhibition of IRF-and STAT-dependent immune responses. 2019;9:3086.

Swanzy EJMSL. COVID-19 fear and performance of workers: A moderated mediation role of organizational support and mental wellbeing. 2022;12(2):81-8.

Costa VGd, Saivish MV, Rodrigues RL, Lima Silva RFd, Moreli ML, Krüger RHJPo. Molecular and serological surveys of canine distemper virus: A meta-analysis of cross-sectional studies. 2019;14(5):e0217594.

Decaro N, Buonavoglia C, Barrs VJVm. Canine parvovirus vaccination and immunisation failures: Are we far from disease eradication? 2020;247:108760.

Vannucchi CIJRBRA. Reposição de colostro no neonato: o que, quando e como administrar? 2022;46(4):360-3.

Shams F, Pourtaghi HJVM, Science. Effect of maternally derived antibodies on two commercial vaccines in changes of serum antibody titres against distemper in puppies. 2023;9(2):698-703.

Engmann C, Fleming JA, Khan S, Innis BL, Smith JM, Hombach J, et al. Closer and closer? Maternal immunization: current promise, future horizons. 2020;40(6):844-57.

Vila Nova B, Cunha E, Sepúlveda N, Oliveira M, São Braz B, Tavares L, et al. Evaluation of the humoral immune response induced by vaccination for canine distemper and parvovirus: a pilot study. 2018;14:1-8.

Vermillion MS, Klein SLJnV. Pregnancy and infection: using disease pathogenesis to inform vaccine strategy. 2018;3(1):6.

Gu X-X, Plotkin SA, Edwards KM, Sette A, Mills KH, Levy O, et al. Waning immunity and microbial vaccines—workshop of the National Institute of Allergy and Infectious Diseases. 2017;24(7):e00034-17.

Pereira M, Valério-Bolas A, Saraiva-Marques C, Alexandre-Pires G, Pereira da Fonseca I, Santos-Gomes GJVs. Development of dog immune system: from in uterus to elderly. 2019;6(4):83.

Zhang W, Zhu C, Xiao F, Liu X, Xie A, Chen F, et al. PH-controlled release of antigens using mesoporous silica nanoparticles delivery system for developing a fish oral vaccine. 2021;12:644396.

Kim C-G, Lee J-C, Ju D-B, Kim S-K, Yun C-H, Cho C-SJTE, et al. Enhancement of immune responses elicited by nanovaccines through a cross-presentation pathway. 2023;20(3):355-70.

Lassaunière R, Polacek C, Gram GJ, Frische A, Tingstedt JL, Krüger M, et al. Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2. 2021;6(1):156.

Zareie P, Farenc C, La Gruta NLJVi. MHC restriction: Where are We now? 2020;33(3):179-87.

Chen C, Chen A, Yang YJFiI. A diversified role for γδT cells in vector-borne diseases. 2022;13:965503.

Silveira MM, Moreira GMSG, Mendonça MJLs. DNA vaccines against COVID-19: Perspectives and challenges. 2021;267:118919.

Celis-Giraldo CT, López-Abán J, Muro A, Patarroyo MA, Manzano-Román RJV. Nanovaccines against animal pathogens: The latest findings. 2021;9(9):988.

Broutin M, Costa F, Peltier S, Maye J, Versillé N, Klonjkowski BJV. An Oil-Based Adjuvant Improves Immune Responses Induced by Canine Adenovirus-Vectored Vaccine in Mice. 2023;15(8):1664.

Rapaka RR, Cross AS, McArthur MAJV. Using adjuvants to drive T cell responses for next-generation infectious disease vaccines. 2021;9(8):820.

Villumsen KR, Koppang EO, Raida MKJF, immunology s. Adverse and long-term protective effects following oil-adjuvanted vaccination against Aeromonas salmonicida in rainbow trout. 2015;42(1):193-203.

Luo X, Song Z, Zeng X, Ye Y, Zheng H, Cai D, et al. A promising self-nanoemulsifying adjuvant with plant-derived saponin D boosts immune response and exerts an anti-tumor effect. 2023;14:1154836.

Filipić B, Pantelić I, Nikolić I, Majhen D, Stojić-Vukanić Z, Savić S, et al. Nanoparticle-based adjuvants and delivery systems for modern vaccines. 2023;11(7):1172.

Ou BS, Baillet J, Picece VC, Gale EC, Powell AE, Saouaf OM, et al. Nanoparticle-Conjugated Toll-Like Receptor 9 Agonists Improve the Potency, Durability, and Breadth of COVID-19 Vaccines. 2024;18(4):3214-33.

Song L, Shan H, Huang JJFiVS. Development of HEK293T-produced recombinant receptor-Fc proteins as potential candidates against canine distemper virus. 2023;10:1180673.

Ceri V, Cicek IJP, health, medicine. Psychological well-being, depression and stress during COVID-19 pandemic in Turkey: a comparative study of healthcare professionals and non-healthcare professionals. 2021;26(1):85-97.

Wallace RM, Cliquet F, Fehlner-Gardiner C, Fooks AR, Sabeta CT, Setién AA, et al. Role of oral rabies vaccines in the elimination of dog-mediated human rabies deaths. 2020;26(12).

Vora NM, Hannah L, Walzer C, Vale MM, Lieberman S, Emerson A, et al. Interventions to reduce risk for pathogen spillover and early disease spread to prevent outbreaks, epidemics, and pandemics. 2023;29(3).

Clemmons EA, Alfson KJ, Dutton III JWJA. Transboundary animal diseases, an overview of 17 diseases with potential for global spread and serious consequences. 2021;11(7):2039.

Chirico F, Ferrari G, Nucera G, Szarpak L, Crescenzo P, Ilesanmi OJJHSS. Prevalence of anxiety, depression, burnout syndrome, and mental health disorders among healthcare workers during the COVID-19 pandemic: a rapid umbrella review of systematic reviews. 2021;6(2):209-20.

Annas S, Zamri-Saad MJA. Intranasal vaccination strategy to control the COVID-19 pandemic from a veterinary medicine perspective. 2021;11(7):1876.

Mourya DT, Yadav PD, Mohandas S, Kadiwar R, Vala M, Saxena AK, et al. Canine distemper virus in Asiatic lions of Gujarat State, India. 2019;25(11):2128.

Nuwarda RF, Ramzan I, Weekes L, Kayser VJV. Vaccine hesitancy: contemporary issues and historical background. 2022;10(10):1595.

Sogbesan A, Bakare A, van Wees SH, Salako J, Bakare D, Olojede OE, et al. Exploring COVID-19 Pandemic Perceptions and Vaccine Uptake among Community Members and Primary Healthcare Workers in Nigeria: A Mixed Methods Study. 2024:2024.09. 02.24312966.

Haeder SFJV. Assessing vaccine hesitancy and support for vaccination requirements for pets and potential spillovers from humans. 2023;41(49):7322-32.

Motta M, Motta G, Stecula DJV. Sick as a dog? The prevalence, politicization, and health policy consequences of canine vaccine hesitancy (CVH). 2023;41(41):5946-50.

Ledda C, Costantino C, Cuccia M, Maltezou HC, Rapisarda VJIjoer, health p. Attitudes of Healthcare Personnel towards Vaccinations before and during the COVID-19 Pandemic. 2021;18(5):2703.

Sinumvayo JP, Munezero PC, Tope AT, Adeyemo RO, Bale MI, Nyandwi JB, et al. Advancing Vaccinology Capacity: Education and Efforts in Vaccine Development and Manufacturing across Africa. 2024;12(7).

Enayati S, Campbell JF, Li HJvX. Vaccine distribution with drones for less developed countries: A case study in Vanuatu. 2023;14:100312.

Kaur GJMM, report mw. Routine vaccination coverage—worldwide, 2022. 2023;72.